Refine
Year of publication
Language
- English (41) (remove)
Has Fulltext
- yes (41)
Is part of the Bibliography
- no (41)
Keywords
- Health care (2)
- Multimorbidity (2)
- Multiple chronic conditions (2)
- Polypharmacy (2)
- Adhesion (1)
- Advanced breast cancer (1)
- Antihormone therapy (1)
- BG-index (1)
- Biochemistry (1)
- Bipolar disorder (1)
- Breast cancer (1)
- COVID-19 (1)
- CVID (1)
- CXCL12 (1)
- CXCR4 (1)
- Cardiology (1)
- Clinical variation (1)
- Completed suicide (1)
- Depression (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Elderly (1)
- European Society for Immunodeficiencies (ESID) (1)
- Frailty (1)
- General practice (1)
- General practitioners (1)
- Genetics (1)
- German PID-NET registry (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- Health services (1)
- Heregulin (1)
- Hypertension (1)
- IgG substitution therapy (1)
- Immunology (1)
- KCGS (1)
- MACE (1)
- MM-121 (1)
- Medication changes (1)
- Metastatic (1)
- NXF1 (1)
- Neuroscience (1)
- Older adults (1)
- Oldest-old (1)
- Oncology (1)
- PID prevalence (1)
- Pandemic (1)
- Patients (1)
- Population-based screening (1)
- Primary health care (1)
- RNA Biology (1)
- Recall rate (1)
- Red blood cell transfusion (1)
- SARS-CoV2 (1)
- SR protein (1)
- SRSF3 (1)
- SRSF7 (1)
- Seribantumab (1)
- Suicide attempt (1)
- T-DM1 (1)
- academic medicine (1)
- advanced breast cancer (1)
- alternative 3′ end processing (1)
- anaemia (1)
- antihormone therapy (1)
- atherosclerosis (1)
- cardiovascular disease (1)
- career promotion (1)
- chemogenomic set (1)
- chemotherapy (1)
- drug discovery (1)
- druggable genome (1)
- elderly patients (1)
- epigenetics (1)
- gender difference (1)
- hemodialysis (1)
- iCLIP (1)
- integrins (1)
- iron deficiency (1)
- kidney disease (1)
- kinase inhibitor (1)
- lapatinib (1)
- mRNA export (1)
- medical error (1)
- metastatic (1)
- miRNA (1)
- next-generation sequencing (1)
- patient blood management (1)
- patient safety (1)
- pertuzumab (1)
- phenotypic screening (1)
- preoperative anaemia management (1)
- primary health care (1)
- primary immunodeficiency (PID) (1)
- promotion index (1)
- prostate carcinoma cells (1)
- protein kinase (1)
- registry for primary immunodeficiency (1)
- risk management (1)
- small molecules (1)
- surgery (1)
- trastuzumab (1)
- understudied kinase (1)
Institute
- Medizin (41) (remove)
Background: In oldest-old patients (>80), few trials showed efficacy of treating hypertension and they included mostly the healthiest elderly. The resulting lack of knowledge has led to inconsistent guidelines, mainly based on systolic blood pressure (SBP), cardiovascular disease (CVD) but not on frailty despite the high prevalence in oldest-old. This may lead to variation how General Practitioners (GPs) treat hypertension. Our aim was to investigate treatment variation of GPs in oldest-olds across countries and to identify the role of frailty in that decision.
Methods: Using a survey, we compared treatment decisions in cases of oldest-old varying in SBP, CVD, and frailty. GPs were asked if they would start antihypertensive treatment in each case. In 2016, we invited GPs in Europe, Brazil, Israel, and New Zealand. We compared the percentage of cases that would be treated per countries. A logistic mixed-effects model was used to derive odds ratio (OR) for frailty with 95% confidence intervals (CI), adjusted for SBP, CVD, and GP characteristics (sex, location and prevalence of oldest-old per GP office, and years of experience). The mixed-effects model was used to account for the multiple assessments per GP.
Results: The 29 countries yielded 2543 participating GPs: 52% were female, 51% located in a city, 71% reported a high prevalence of oldest-old in their offices, 38% and had >20 years of experience. Across countries, considerable variation was found in the decision to start antihypertensive treatment in the oldest-old ranging from 34 to 88%. In 24/29 (83%) countries, frailty was associated with GPs’ decision not to start treatment even after adjustment for SBP, CVD, and GP characteristics (OR 0.53, 95%CI 0.48–0.59; ORs per country 0.11–1.78).
Conclusions: Across countries, we found considerable variation in starting antihypertensive medication in oldest-old. The frail oldest-old had an odds ratio of 0.53 of receiving antihypertensive treatment. Future hypertension trials should also include frail patients to acquire evidence on the efficacy of antihypertensive treatment in oldest-old patients with frailty, with the aim to get evidence-based data for clinical decision-making.